Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

Published:2014-10-24 Issue:1 Volume:13 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Iida Mari,Brand Toni M,Starr Megan M,Huppert Evan J,Luthar Neha,Bahrar Harsh,Coan John P,Pearson Hannah E,Salgia Ravi,Wheeler Deric L

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/1476-4598-13-242.pdf

Reference56 articles.

1. Wheeler DL, Dunn EF, Harari PM: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010, 7: 493-507. 10.1038/nrclinonc.2010.97

2. Yarden Y, Pines G: The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012, 12: 553-563. 10.1038/nrc3309

3. Ang KK, Andratschke NH, Milas L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004, 58: 959-965. 10.1016/j.ijrobp.2003.07.010

4. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer. 2001, 37 (Suppl 4): S9-S15.

5. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G, Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996, 74: 1253-1257. 10.1038/bjc.1996.525

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Horizontal gene transfer of Cccyt contributes to virulence of mycoparasite Calcarisporium cordycipiticola by interacting with a host heat shock protein;International Journal of Biological Macromolecules;2023-07

2. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor;Pharmacological Reviews;2023-06-20

3. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer;Frontiers in Immunology;2023-04-20

4. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review);World Academy of Sciences Journal;2022-09-05

5. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3